TY - JOUR T1 - Prolonged Response to Early Docetaxel in a Patient with Biochemical Relapse after Primary Therapy for Prostate Cancer and Incomplete Response to Androgen Suppression Therapy JF - Anticancer Research JO - Anticancer Res SP - 973 LP - 974 VL - 31 IS - 3 AU - CHRISTINE M. BARNETT AU - JASON F. FLAMIATOS AU - TOMASZ M. BEER Y1 - 2011/03/01 UR - http://ar.iiarjournals.org/content/31/3/973.abstract N2 - Sensitivity to androgen suppression therapy (AST) is a key determinant of survival in patients with non-localized prostate cancer. While an incomplete response to AST is associated with poor survival, additional therapy is typically withheld until obvious cancer progression. It is not known if the application of additional therapy earlier can have a favorable impact on long-term outcomes. We present the case of a patient with biochemically relapsed prostate cancer treated with early docetaxel after initial incomplete response to AST who now has a prolonged response to therapy. ER -